Shenzhen Beike Biotechnology Co., Ltd. (Beike Biotechnology) is a Chinese biotechnology company based in Shenzhen that specializes in the research, clinical translation and technology support services of adult stem cells. Beike Biotechnology was founded in July 2005 with investment from Peking University, Hong Kong University of Science and Technology and Shenzhen City Hall and has recruited more than 700 employees since its inception. This elite research and development team is led by the most distinguished scholars and scientists from the stem cell field.
After 6 years of operation, Beike Biotechnology now has 7 subsidiaries: Jiangsu Beike, Anhui Beike, Guizhou Beike, Henan Beike, Liaoning Beike, Beike (Hong Kong) International and Beike (India) International.
Global clinical research and technical support network
Beike Biotechnology has provided clinical-grade stem cells and technical support services to over 70 Chinese medical institutions and to countries in Southeast Asia, the Middle East and Europe. Beike Biotechnology’s service network includes stem cell storage, stem cell testing, stem cell clinical translation, R&D of stem cell technologies and products, stem cell drug screening, stem cell technology exchange and employee training.
The largest comprehensive stem cell banks in Asia
Beike Biotechnology’s first stem cell banks include the Jiangsu, Shenzhen and Anhui stem cell banks, with a total area of 323,000 square feet, a total storage capacity of over two million units and a total investment of nearly $80 million. Beike Biotechnology’s second project includes stem cell banks in Liaoning, Henan, Guizhou, and India, with a total designed storage capacity of nearly ten million units.
Strength in Research & Development
Beike Biotechnology has an outstanding stem cell research team that includes over three hundred technical staff and over ten scientists with PhD degrees. Nearly 100 papers have been published in internationally renowned publications including Nature Reviews Rheumatology and Stem Cell. Beike Biotechnology owns 21 patents and has undertaken 27 government research projects. Beike Biotechnology was accredited as a national high-tech enterprise and became a member of the International Society for Cellular Therapy (ISCT) in 2009.
Strict quality control systems
Beike Biotechnology has established more than 20 adult stem cell processing laboratories, in accordance with GMP standards, and has been awarded ISO9001 and ISO17025 certificates. Jiangsu Beike’s inspection center was accredited by the China National Accreditation Service for Conformity Assessment (CNAS) in 2011, and it is the first adult stem cell processing laboratory accredited by CNAS. Beike Biotechnology also successfully completed on-site evaluation for American Association of Blood Bank (AABB) accreditation in September 2011.
